# BetterLife Pharma Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BetterLife Pharma Inc.). ## Overview BetterLife Pharma Inc. is a Vancouver-based biotechnology company developing pharmaceutical candidates for neurological and neuropsychiatric disorders. Its lead program, BETR-001, is a non-hallucinogenic, non-controlled LSD derivative in preclinical and IND-enabling development, while the company also owns a viral-infection drug candidate and operates through Canadian, Australian, and Hong Kong subsidiaries. ## Products & services • BETR-001 neurological-disorder drug candidate • BETR-001 synthesis and formulation technology • BETR-001 composition and method-of-use intellectual property • Viral-infection drug candidate • Preclinical and IND-enabling development - **BETR-001** (70%) — A non-hallucinogenic LSD derivative being developed for neurological and neuropsychiatric disorders. - **Viral-infection candidate** (15%) — A drug candidate owned by BetterLife for potential treatment of viral infections. - **Intellectual property and development platform** (15%) — Patents and development capabilities supporting compound synthesis, composition, and therapeutic uses. - BETR-001 neurological-disorder drug candidate - BETR-001 synthesis and formulation technology - BETR-001 composition and method-of-use intellectual property - Viral-infection drug candidate - Preclinical and IND-enabling development ## Customers BetterLife is primarily a development-stage pharmaceutical company, so its immediate commercial counterparties are expected to be research collaborators, licensing partners, strategic investors, and potential pharmaceutical acquirers rather than a broad base of end patients. Future customers could include healthcare providers, distributors, and patients if BETR-001 or another candidate reaches approval and commercialization. The company’s value proposition to partners is centered on differentiated neurological drug candidates and associated intellectual property. - **Pharmaceutical licensing partners** (primary) — May license or acquire BETR-001 to access its neurological indications and related patent rights. - **Biotechnology collaborators** (secondary) — Support preclinical, IND-enabling, regulatory, and clinical development activities. - **Strategic investors** (primary) — Provide capital to fund drug development in exchange for equity or convertible securities. - **Healthcare providers and distributors** (emerging) — Potential future channels for approved neurological or antiviral medicines. - **Patients** (emerging) — Potential end users of approved therapies for neurological or viral conditions. - Pharmaceutical partners seeking neurological drug candidates - Biotechnology collaborators supporting preclinical development - Licensing or acquisition partners seeking patent assets - Healthcare providers and distributors are future end-market buyers - Patients with neurological or neuropsychiatric disorders are eventual users ## Geography BetterLife is headquartered in Vancouver, British Columbia, Canada, and its consolidated structure includes Canadian subsidiaries as well as operations through Altum Pharma in Australia and Altum Pharmaceuticals in Hong Kong. The available reports do not disclose country-level revenue, and the company’s geographic exposure currently reflects research, corporate, and subsidiary activities rather than an established commercial sales footprint. - Vancouver, Canada is the corporate headquarters - MedMelior and Blife Therapeutics are Canadian subsidiaries - Altum Pharma provides an Australian subsidiary presence - Altum Pharmaceuticals provides a Hong Kong subsidiary presence - No country-level revenue is disclosed in the available reports ## Strategy BetterLife’s strategy centers on advancing BETR-001 through preclinical and IND-enabling studies for neurological and neuropsychiatric indications. The company seeks to use BETR-001’s non-hallucinogenic profile and intellectual property position to address development and regulatory considerations associated with psychedelic-derived medicines. It is also evaluating strategic alternatives for its viral-infection candidate while relying on equity or debenture financing to fund operations and development. - **Advance BETR-001 development** (short-term) — Progress toward regulatory readiness is needed to validate the lead asset and attract partners. - **Build value from intellectual property** (medium-term) — Patent protection can support licensing, partnering, and future commercialization economics. - **Determine a path for the viral candidate** (medium-term) — A strategic transaction or partner could monetize an asset outside the core neurological focus. - **Secure development financing** (short-term) — Clinical and regulatory programs require capital before product revenue is available. - Advance BETR-001 through preclinical and IND-enabling studies - Develop neurological and neuropsychiatric treatment indications - Leverage BETR-001 synthesis and composition patents - Evaluate strategic alternatives for the viral-infection candidate - Raise equity or debenture capital to fund development ## Risks BetterLife remains dependent on external financing while its lead candidate is preclinical, creating substantial execution and going-concern risk before any commercial product revenue. BETR-001 may fail in development, face regulatory or patent challenges, or prove difficult to commercialize, while the company also has exposure to dilution and debt-conversion activity. The broader biotech model adds trial, manufacturing, partner-dependence, competitive, and reimbursement risks. - **Going-concern and financing risk** [critical] — Management states that additional equity or debenture financing may not be available on acceptable terms or on time. - **Clinical and development failure** [critical] — BETR-001 is still in preclinical and IND-enabling studies, so safety or efficacy remains unproven. - **Regulatory approval risk** [high] — Non-hallucinogenic and non-controlled characteristics do not eliminate requirements for regulatory review and clinical evidence. - **Shareholder dilution** [high] — Debt conversions and future equity financing increase the share count and may reduce existing ownership percentages. - **Intellectual-property risk** [high] — Patent claims may be challenged, circumvented, or insufficient to prevent competing neurological therapies. - **Partnering and commercialization risk** [high] — The company may need strategic partners for development, manufacturing, regulatory execution, and market access. - Preclinical results may not translate into clinical efficacy - Regulatory authorities may reject or delay BETR-001 development - External financing may be unavailable or costly - Equity and debt conversions can dilute existing shareholders - Patent protection may face validity or infringement challenges - Viral-candidate development may lack a strategic partner ## Accounting The interim statements are prepared on a consolidated basis in Canadian dollars and include MedMelior and its controlled subsidiaries, with non-controlling interests recorded for the portion not owned by BetterLife. Management’s disclosed going-concern uncertainty is particularly important because the statements do not include adjustments that could be required if operations cannot continue. Investors should also monitor the valuation of development assets, share-based compensation, and convertible debenture conversions because these estimates and financing instruments can materially affect assets, liabilities, expenses, and diluted share counts. - **Going-concern assessment** — Potential material adjustments to assets and liabilities if the company cannot continue operations. - **Consolidation and non-controlling interests** — Reported assets, liabilities, revenue, expenses, equity, and net loss include consolidated subsidiary activity. - **Research and development asset valuation** — Failed programs could require impairment or write-offs of capitalized development-related assets. - **Convertible debenture accounting** — Conversions affect liabilities, equity, finance costs, warrants, and diluted share calculations. - **Share-based compensation** — Option grants can increase operating expenses and future diluted shares. - Going-concern uncertainty may require future balance-sheet adjustments - Consolidation includes Canadian, Australian, and Hong Kong subsidiaries - Non-controlling interests affect consolidated equity and net loss - Development assets require impairment and recoverability judgments - Convertible debentures can change liabilities and diluted shares - Stock options create share-based compensation expense --- *Last updated: 2026-09-08T05:12:07.775361+00:00*